Combined targeted treatment in early onset epilepsy associated with tuberous sclerosis

Area of Science:

• Neurology
• Pediatrics
• Genetics

Background:

• Tuberous sclerosis complex (TSC) is a genetic disorder affecting multiple organs.
• Epilepsy is a common comorbidity in TSC, occurring in up to 85% of cases, often with onset in infancy.
• Early epilepsy intervention is critical for neurodevelopmental outcomes in TSC.

Purpose of the Study:

• To report a case of infantile spasms in a child with TSC.
• To evaluate the impact of early combined treatment with vigabatrin and everolimus on seizure control and neurodevelopmental outcomes.
• To discuss potential implications for treatment timing and management strategies in TSC-related epilepsy.

Main Methods:

• Case report of a pediatric patient diagnosed with TSC.
• Initiation of vigabatrin for infantile spasms at 6 months of age.
• Addition of everolimus at 18 months due to subependymal giant cell astrocytoma.

Main Results:

• The patient experienced infantile spasms at 6 months, treated promptly with vigabatrin.
• Despite combined treatment with vigabatrin and everolimus, the patient continues to have focal motor seizures.
• At 40 months, the child exhibits severe developmental delay and autism-like behaviors.

Conclusions:

• Early and targeted treatment for epilepsy in TSC may not always prevent severe neurodevelopmental impairments.
• The case suggests a need for further research into optimal treatment timing and combination therapies for TSC-associated epilepsy.
• Aggressive management is crucial, but outcomes can still be challenging in some TSC cases.